Prostatic Specific Antigen. From Its Early Days...

Incisión Endoscópica Del Cuello Vesical Como ...

Carcinoma Renal De Células Claras Metastatizad...

Biopsia Transrectal Ecodirigida Convencional. P...

Advanced Stage Fibrosarcoma Of The Spermatic Cord.

0 votes
Prostatic Specific Antigen. From Its Early Days Until Becoming A Prostate Cancer Biomarker.
Autor: T. Dellavedova.
Editorial: Archivos Españoles de Urología
5 páginas
Pago único: €14.88
Requiere suscripción: Académico
Tipo de publicación: Articulo
Follow this publisher

Comparte esta publicación:


Prostate-specific antigen (PSA) has been

since the mid 80’s the most commonly used biomarker for

measuring current and future risk of prostate cancer, for

its early detection and to measure response to treatments

and detecting recurrence in all stages of the disease.

PSA’s early development came along with progress in

the field of immunology, which allowed detection and

study of antigens from different tissues and fluids when

injecting them into rabbits to promote immune response.

Rubin Flocks in 1960 was the first to investigate and

discover prostate-specific antigens in benign and

malignant tissue. Some years later, Hara, a Japanese

forensic investigator, found “gamma seminoprotein”, that

he used to detect human semen in rape cases. However,

his work published in Japanese did not reach the Englishspeaking

scientific community.

In 1970 Ablin discovered both in prostatic fluid and

tissue what he called “prostate-specific antigen”, but he

didn’t characterize or describe it.

Investigators Li and Beling, and Sensabaugh,

approached the current PSA, but they were limited by

available technology at that time.

Dr T Ming Chu led a research team on prostate cancer in

New York, USA and published their results in 1979. He

finally received the patent for the discovery of “human

purified prostate antigen” in 1984. Due to this work, the

Food and Drug Administration (FDA), in USA, approved

the use of PSA for monitoring recurrence after treatment.

It was later known that PSA was not prostate-specific

since it was produced in other tissues and fluids, but it

was recognized that it was human species-specific.

Works by Papsidero and Stamey showed new indications

and utilities for PSA, but it was Catalona who first used

it as a marker for prostate cancer in 1991. Thanks to

these advances FDA authorized in 1994 the clinical use

of PSA for early detection of prostate cancer.

Sobre el editor:

Revista Internacional de Urología indexada y peer-reviewed, fundada en 1944, dirigida a toda la comunidad científica. Aquí encontrarás las últimas novedades y hallazgos urológicos. Publicamos 10 números anuales.